Cargando…

Large-scale pharmacological profiling of 3D tumor models of cancer cells

The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathews Griner, Lesley A, Zhang, Xiaohu, Guha, Rajarshi, McKnight, Crystal, Goldlust, Ian S, Lal-Nag, Madhu, Wilson, Kelli, Michael, Sam, Titus, Steve, Shinn, Paul, Thomas, Craig J, Ferrer, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261027/
https://www.ncbi.nlm.nih.gov/pubmed/27906188
http://dx.doi.org/10.1038/cddis.2016.360
_version_ 1782499505675960320
author Mathews Griner, Lesley A
Zhang, Xiaohu
Guha, Rajarshi
McKnight, Crystal
Goldlust, Ian S
Lal-Nag, Madhu
Wilson, Kelli
Michael, Sam
Titus, Steve
Shinn, Paul
Thomas, Craig J
Ferrer, Marc
author_facet Mathews Griner, Lesley A
Zhang, Xiaohu
Guha, Rajarshi
McKnight, Crystal
Goldlust, Ian S
Lal-Nag, Madhu
Wilson, Kelli
Michael, Sam
Titus, Steve
Shinn, Paul
Thomas, Craig J
Ferrer, Marc
author_sort Mathews Griner, Lesley A
collection PubMed
description The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do not reproduce the cellular complexity of tumors and their microenvironment in vivo. The use of three-dimensional (3D) cellular systems have been explored as enabling more predictive in vitro tumor models for drug discovery. To date, small-scale screens have demonstrated that pharmacological responses tend to differ between 2D and 3D cancer cell growth models. However, the limited scope of screens using 3D models has not provided a clear delineation of the cellular pathways and processes that differentially regulate cell survival and death in the different in vitro tumor models. Here we sought to further understand the differences in pharmacological responses between cancer tumor cells grown in different conditions by profiling a large collection of 1912 chemotherapeutic agents. We compared pharmacological responses obtained from cells cultured in traditional 2D monolayer conditions with those responses obtained from cells forming spheres versus cells already in 3D spheres. The target annotation of the compound library screened enabled the identification of those key cellular pathways and processes that when modulated by drugs induced cell death in all growth conditions or selectively in the different cell growth models. In addition, we also show that many of the compounds targeting these key cellular functions can be combined to produce synergistic cytotoxic effects, which in many cases differ in the magnitude of their synergism depending on the cellular model and cell type. The results from this work provide a high-throughput screening framework to profile the responses of drugs both as single agents and in pairwise combinations in 3D sphere models of cancer cells.
format Online
Article
Text
id pubmed-5261027
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52610272017-01-26 Large-scale pharmacological profiling of 3D tumor models of cancer cells Mathews Griner, Lesley A Zhang, Xiaohu Guha, Rajarshi McKnight, Crystal Goldlust, Ian S Lal-Nag, Madhu Wilson, Kelli Michael, Sam Titus, Steve Shinn, Paul Thomas, Craig J Ferrer, Marc Cell Death Dis Original Article The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do not reproduce the cellular complexity of tumors and their microenvironment in vivo. The use of three-dimensional (3D) cellular systems have been explored as enabling more predictive in vitro tumor models for drug discovery. To date, small-scale screens have demonstrated that pharmacological responses tend to differ between 2D and 3D cancer cell growth models. However, the limited scope of screens using 3D models has not provided a clear delineation of the cellular pathways and processes that differentially regulate cell survival and death in the different in vitro tumor models. Here we sought to further understand the differences in pharmacological responses between cancer tumor cells grown in different conditions by profiling a large collection of 1912 chemotherapeutic agents. We compared pharmacological responses obtained from cells cultured in traditional 2D monolayer conditions with those responses obtained from cells forming spheres versus cells already in 3D spheres. The target annotation of the compound library screened enabled the identification of those key cellular pathways and processes that when modulated by drugs induced cell death in all growth conditions or selectively in the different cell growth models. In addition, we also show that many of the compounds targeting these key cellular functions can be combined to produce synergistic cytotoxic effects, which in many cases differ in the magnitude of their synergism depending on the cellular model and cell type. The results from this work provide a high-throughput screening framework to profile the responses of drugs both as single agents and in pairwise combinations in 3D sphere models of cancer cells. Nature Publishing Group 2016-12 2016-12-01 /pmc/articles/PMC5261027/ /pubmed/27906188 http://dx.doi.org/10.1038/cddis.2016.360 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Mathews Griner, Lesley A
Zhang, Xiaohu
Guha, Rajarshi
McKnight, Crystal
Goldlust, Ian S
Lal-Nag, Madhu
Wilson, Kelli
Michael, Sam
Titus, Steve
Shinn, Paul
Thomas, Craig J
Ferrer, Marc
Large-scale pharmacological profiling of 3D tumor models of cancer cells
title Large-scale pharmacological profiling of 3D tumor models of cancer cells
title_full Large-scale pharmacological profiling of 3D tumor models of cancer cells
title_fullStr Large-scale pharmacological profiling of 3D tumor models of cancer cells
title_full_unstemmed Large-scale pharmacological profiling of 3D tumor models of cancer cells
title_short Large-scale pharmacological profiling of 3D tumor models of cancer cells
title_sort large-scale pharmacological profiling of 3d tumor models of cancer cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261027/
https://www.ncbi.nlm.nih.gov/pubmed/27906188
http://dx.doi.org/10.1038/cddis.2016.360
work_keys_str_mv AT mathewsgrinerlesleya largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT zhangxiaohu largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT guharajarshi largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT mcknightcrystal largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT goldlustians largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT lalnagmadhu largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT wilsonkelli largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT michaelsam largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT titussteve largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT shinnpaul largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT thomascraigj largescalepharmacologicalprofilingof3dtumormodelsofcancercells
AT ferrermarc largescalepharmacologicalprofilingof3dtumormodelsofcancercells